Duration of vaginal retention and potential duration of antiviral activity for five nonoxynol-9 containing intravaginal contraceptives

Frank R Witter, P. Barditch-Crovo, L. Rocco, C. B. Trapnell

Research output: Contribution to journalArticle

Abstract

Objective: The purpose of this study was to determine the vaginal retention of five nonoxynol-9 intravaginal contraceptives. Method: An open- label crossover study in 10 premenopausal volunteers was performed at an outpatient clinical research center. The outcomes are described utilizing the median and range. Result: At 8 h post-instillation, the median amounts of nonoxynol-9 present in the vagina were: Delfon® 7.68 mg, Conceptrol® 5.18 mg, Advantage 24® 1.95 mg, VCF® 1.74 mg, and Semicid® 1.51 mg respectively. Our calculated theoretical minimal amount needed to protect against HIV infection is 2.00 mg. Conclusion: The best vehicle for retaining nonoxynol-9 in the vagina appears to be foam. Further research in the effectiveness of nonoxynol-9 in prevention of the spread of HIV infection should be directed toward the use of foam vehicles to deliver nonoxynol-9 to the vagina.

Original languageEnglish (US)
Pages (from-to)165-170
Number of pages6
JournalInternational Journal of Gynecology and Obstetrics
Volume65
Issue number2
DOIs
StatePublished - May 1 1999

Fingerprint

Nonoxynol
Contraceptive Agents
Antiviral Agents
Vagina
HIV Infections
Research
Cross-Over Studies
Volunteers
Outpatients

Keywords

  • AIDS
  • Contraception
  • HIV
  • Nonoxynol-9
  • Vagina

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Duration of vaginal retention and potential duration of antiviral activity for five nonoxynol-9 containing intravaginal contraceptives. / Witter, Frank R; Barditch-Crovo, P.; Rocco, L.; Trapnell, C. B.

In: International Journal of Gynecology and Obstetrics, Vol. 65, No. 2, 01.05.1999, p. 165-170.

Research output: Contribution to journalArticle

@article{88953484a65d421ba31348e868912737,
title = "Duration of vaginal retention and potential duration of antiviral activity for five nonoxynol-9 containing intravaginal contraceptives",
abstract = "Objective: The purpose of this study was to determine the vaginal retention of five nonoxynol-9 intravaginal contraceptives. Method: An open- label crossover study in 10 premenopausal volunteers was performed at an outpatient clinical research center. The outcomes are described utilizing the median and range. Result: At 8 h post-instillation, the median amounts of nonoxynol-9 present in the vagina were: Delfon{\circledR} 7.68 mg, Conceptrol{\circledR} 5.18 mg, Advantage 24{\circledR} 1.95 mg, VCF{\circledR} 1.74 mg, and Semicid{\circledR} 1.51 mg respectively. Our calculated theoretical minimal amount needed to protect against HIV infection is 2.00 mg. Conclusion: The best vehicle for retaining nonoxynol-9 in the vagina appears to be foam. Further research in the effectiveness of nonoxynol-9 in prevention of the spread of HIV infection should be directed toward the use of foam vehicles to deliver nonoxynol-9 to the vagina.",
keywords = "AIDS, Contraception, HIV, Nonoxynol-9, Vagina",
author = "Witter, {Frank R} and P. Barditch-Crovo and L. Rocco and Trapnell, {C. B.}",
year = "1999",
month = "5",
day = "1",
doi = "10.1016/S0020-7292(99)00018-1",
language = "English (US)",
volume = "65",
pages = "165--170",
journal = "International Journal of Gynecology and Obstetrics",
issn = "0020-7292",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Duration of vaginal retention and potential duration of antiviral activity for five nonoxynol-9 containing intravaginal contraceptives

AU - Witter, Frank R

AU - Barditch-Crovo, P.

AU - Rocco, L.

AU - Trapnell, C. B.

PY - 1999/5/1

Y1 - 1999/5/1

N2 - Objective: The purpose of this study was to determine the vaginal retention of five nonoxynol-9 intravaginal contraceptives. Method: An open- label crossover study in 10 premenopausal volunteers was performed at an outpatient clinical research center. The outcomes are described utilizing the median and range. Result: At 8 h post-instillation, the median amounts of nonoxynol-9 present in the vagina were: Delfon® 7.68 mg, Conceptrol® 5.18 mg, Advantage 24® 1.95 mg, VCF® 1.74 mg, and Semicid® 1.51 mg respectively. Our calculated theoretical minimal amount needed to protect against HIV infection is 2.00 mg. Conclusion: The best vehicle for retaining nonoxynol-9 in the vagina appears to be foam. Further research in the effectiveness of nonoxynol-9 in prevention of the spread of HIV infection should be directed toward the use of foam vehicles to deliver nonoxynol-9 to the vagina.

AB - Objective: The purpose of this study was to determine the vaginal retention of five nonoxynol-9 intravaginal contraceptives. Method: An open- label crossover study in 10 premenopausal volunteers was performed at an outpatient clinical research center. The outcomes are described utilizing the median and range. Result: At 8 h post-instillation, the median amounts of nonoxynol-9 present in the vagina were: Delfon® 7.68 mg, Conceptrol® 5.18 mg, Advantage 24® 1.95 mg, VCF® 1.74 mg, and Semicid® 1.51 mg respectively. Our calculated theoretical minimal amount needed to protect against HIV infection is 2.00 mg. Conclusion: The best vehicle for retaining nonoxynol-9 in the vagina appears to be foam. Further research in the effectiveness of nonoxynol-9 in prevention of the spread of HIV infection should be directed toward the use of foam vehicles to deliver nonoxynol-9 to the vagina.

KW - AIDS

KW - Contraception

KW - HIV

KW - Nonoxynol-9

KW - Vagina

UR - http://www.scopus.com/inward/record.url?scp=0033025198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033025198&partnerID=8YFLogxK

U2 - 10.1016/S0020-7292(99)00018-1

DO - 10.1016/S0020-7292(99)00018-1

M3 - Article

C2 - 10405061

AN - SCOPUS:0033025198

VL - 65

SP - 165

EP - 170

JO - International Journal of Gynecology and Obstetrics

JF - International Journal of Gynecology and Obstetrics

SN - 0020-7292

IS - 2

ER -